Who is sponsoring NCT03911336?

NCT03911336 is sponsored by University of Iowa.

What drugs are being tested in NCT03911336?

Interventions in NCT03911336: Group A - test:Tooth extraction and intake of NSAID and a non-NSAID, Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID, Group C - Control 2: tooth extraction and intake of a Non-Nsaid.

What condition does NCT03911336 study?

NCT03911336 studies Tooth Loss.

Is NCT03911336 still recruiting?

NCT03911336 is currently withdrawn. Last updated 21 June 2022.

Last reviewed 2022-06-21 · How we verify

NCT03911336

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Harnessing Chronomodulation to Enhance Osteogenesis

Withdrawn Phase 4 Last updated 21 June 2022

What this trial tests

Phase 4 trial testing Group A - test:Tooth extraction and intake of NSAID and a non-NSAID in Tooth Loss. Withdrawn.

Timeline

1 January 2023

Primary endpoint
1 January 2023

1 January 2023

Quick facts

Lead sponsor	University of Iowa
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	1 January 2023
Primary completion	1 January 2023
Estimated completion	1 January 2023

Drugs / interventions tested

Group A - test:Tooth extraction and intake of NSAID and a non-NSAID — full drug profile →
Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID — full drug profile →
Group C - Control 2: tooth extraction and intake of a Non-Nsaid — full drug profile →

Conditions studied

Tooth Loss — all drugs for Tooth Loss →

Sponsor

University of Iowa

Who can join

Adults 18 to 85, any sex, with Tooth Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronotherapy is an emerging field in biomedicine that leverages on fine-tuning the timing of drug delivery to obtain a therapeutic effect. Dr. Tamimi and his team have successfully harnessed chronotherapy using NSAIDs to enhance bone healing in a murine fracture model. Unpublished findings revealed that mice receiving carprofen for 3 days post-fracture exclusively during activity hours exhibited superior bone healing outcomes in comparison to specimens that received the same drug during resting hours. This is a 3-arm RCT aimed at evaluating the effect of different chronotherapeutic NSAID regimens on intraoral bone healing in humans using an extraction socket healing model in the context of an early implant placement protocol. The primary aim is to elucidate whether there are differences in osteogenesis and in the characteristics of the newly formed bone between patients following different post-operative NSAID chronotherapeutic protocols. Secondary endpoints of interest include assessment of alveolar bone and soft tissue dimensional changes between pre- and post-extraction, implant insertion torque, serum CRP levels, wound healing index and patient-reported discomfort at different time points. If proven beneficial, the proposed chronotherapeutic approach could be readily implemented in clinical practice as a standalone therapy or as a valuable complement to existing standard-of-care protocols, due to its simplicity, safety and cost-effectiveness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tooth Loss

Currently open trials in the same condition.

NCT07393997 — Autogenous Tooth Transplantation With Instrumentally Simulated Open Apex and Platelet-Rich Fibrin · NA · recruiting
NCT07280260 — Clinical Performance of Nobel N1 System · Phase 4 · recruiting
NCT07177521 — Primary Stability and Peri-implant Outcomes of Short Implants in Post-extraction Single-tooth Sites · NA · recruiting
NCT07534514 — Digitally Assisted Immediate Implants in Geriatric Patients · recruiting
NCT06554080 — Survival and Success Rates of External- and Internal- Connection Dental Implants Placed Within the United Kingdom Armed · active not recruiting

Other University of Iowa trials

Trials by the same sponsor.

NCT07224269 — Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis · EARLY_PHASE1 · not yet recruiting
NCT07244809 — Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adve · NA · recruiting
NCT07097961 — Paediatric Post-TB Pulmonary Rehab Study · NA · recruiting
NCT06951594 — Robotic-Assisted Versus Manual Electrode Array Insertion · NA · recruiting
NCT06710119 — Effect of Custom Dynamic Orthoses on Forefoot Loading · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03911336 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Iowa
Last refreshed: 21 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03911336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing